Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

NCT01381822 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma
Gastrointestinal Stromal Tumors
Pancreatic Neuroendocrine Tumors

Interventions

DRUG: TH-302

Sponsor

Threshold Pharmaceuticals